Regulation (EC) No 273/2004 of the European Parliament and of the Council of 11 February 2004 on drug precursors (Text with EEA relevance)

#### ANNEX I

# [F1List of scheduled substances]

# **Textual Amendments**

F1 Substituted by Regulation (EU) No 1258/2013 of the European Parliament and of the Council of 20 November 2013 amending Regulation (EC) No 273/2004 on drug precursors (Text with EEA relevance).

#### CATEGORY 1

Substance	CN designation(if different)	CN code <sup>a</sup>	CAS No <sup>b</sup>
1-phenyl-2- propanone	Phenylacetone	2914 31 00	103-79-7
[F2Methyl alpha- phenylacetoacetate (MAPA)		2918 30 00	16648-44-5
Methyl 2-methyl-3- phenyloxirane-2- carboxylate (BMK methyl glycidate)		2918 99 90	80532-66-7
2-methyl-3- phenyloxirane-2- carboxylic acid (BMK glycidic acid)		2918 99 90	25547-51-7]
N-acetylanthranilic acid	2-acetamidobenzoic acid	2924 23 00	89-52-1
<i>I<sup>F3</sup>Alpha</i> -phenylacetoacetamide (APAA)		2924 29 70	4433-77-6]
<i>I<sup>F4</sup>Alpha</i> -phenylacetoacetonitrile (APAAN)	3	2926 40 00	4468-48-8]
Isosafrol (cis + trans)		2932 91 00	120-58-1
3,4- methylenedioxyphenyl one	1-(1,3- pkepandoxol-5- yl)propan-2-one	2932 92 00	4676-39-5
Piperonal		2932 93 00	120-57-0

**a** OJ L 290, 28.10.2002, p. 1.

b The CAS No is the 'chemical abstracts service registry number', which is a unique numeric identifier specific to each substance and its structure. The CAS No is specific to each isomer and to each salt of each isomer. It must be understood that the CAS Nos for the salts of the substances listed above will be different to those given.

c Also named (+)-norpseudoephedrine, CN code 2939 43 00, CAS No 492-39-7.

Safrole	2932 94 00	94-59-7
I <sup>FS</sup> Methyl 3-(1,3- benzodioxol-5-yl)-2- methyloxirane-2- carboxylate (PMK methyl glycidate	2932 99 00	13605-48-6
3-(1,3-benzodioxol-5-yl)-2-methyloxirane-2-carboxylic acid (PMK glycidic acid)	2932 99 00	2167189-50-4]
[F64-anilino- N - phenethylpiperidine (ANPP)	2933 39 99	21409-26-7
N -phenethyl-4- piperidone (NPP)	2933 39 99	39742-60-4]
Ephedrine	2939 41 00	299-42-3
Pseudoephedrine	2939 42 00	90-82-4
Norephedrine	[F12939 44 00]	14838-15-4
Ergometrine	2939 61 00	60-79-7
Ergotamine	2939 62 00	113-15-5
Lysergic acid	2939 63 00	82-58-6

The stereoisomeric forms of the substances listed in this category not being cathine<sup>c</sup>, whenever the existence of such forms is possible.

The salts of the substances listed in this category, whenever the existence of such salts is possible and not being the salts of cathine.

[F7(1R,2S)-(-)-chloroephedrine	[ <sup>F8</sup> 2939 79 90]	110925-64-9
(1S,2R)-(+)- chloroephedrine	[ <sup>F9</sup> 2939 79 90]	1384199-95-4
(1S,2S)-(+)- chloropseudoephedrine	[F102939 79 90]	73393-61-0
(1R,2R)-(-)- chloropseudoephedrine	[ <sup>F11</sup> 2939 79 90]	771434-80-1]

**a** OJ L 290, 28.10.2002, p. 1.

b The CAS No is the 'chemical abstracts service registry number', which is a unique numeric identifier specific to each substance and its structure. The CAS No is specific to each isomer and to each salt of each isomer. It must be understood that the CAS Nos for the salts of the substances listed above will be different to those given.

c Also named (+)-norpseudoephedrine, CN code 2939 43 00, CAS No 492-39-7.

#### **Textual Amendments**

- **F2** Inserted by Commission Delegated Regulation (EU) 2020/1737 of 14 July 2020 amending Regulation (EC) No 273/2004 of the European Parliament and of the Council and Council Regulation (EC) No 111/2005 as regards the inclusion of certain drug precursors in the list of scheduled substances (Text with EEA relevance)
- **F3** Inserted by Commission Delegated Regulation (EU) 2020/1737 of 14 July 2020 amending Regulation (EC) No 273/2004 of the European Parliament and of the Council and Council Regulation (EC) No 111/2005 as regards the inclusion of certain drug precursors in the list of scheduled substances (Text with EEA relevance)
- **F4** Substituted by Commission Delegated Regulation (EU) 2020/1737 of 14 July 2020 amending Regulation (EC) No 273/2004 of the European Parliament and of the Council and Council Regulation (EC) No 111/2005 as regards the inclusion of certain drug precursors in the list of scheduled substances (Text with EEA relevance)
- F5 Inserted by Commission Delegated Regulation (EU) 2020/1737 of 14 July 2020 amending Regulation (EC) No 273/2004 of the European Parliament and of the Council and Council Regulation (EC) No 111/2005 as regards the inclusion of certain drug precursors in the list of scheduled substances (Text with EEA relevance)
- **F6** Inserted by Commission Delegated Regulation (EU) 2018/729 of 26 February 2018 amending Regulation (EC) No 273/2004 of the European Parliament and of the Council and Council Regulation (EC) No 111/2005 as regards the inclusion of certain drug precursors in the list of scheduled substances (Text with EEA relevance).
- F7 Inserted by Commission Delegated Regulation (EU) 2016/1443 of 29 June 2016 amending Regulation (EC) No 273/2004 of the European Parliament and of the Council and Council Regulation (EC) No 111/2005 as regards the inclusion of certain drug precursors in the list of scheduled substances (Text with EEA relevance).
- **F8** Substituted by Commission Delegated Regulation (EU) 2020/1737 of 14 July 2020 amending Regulation (EC) No 273/2004 of the European Parliament and of the Council and Council Regulation (EC) No 111/2005 as regards the inclusion of certain drug precursors in the list of scheduled substances (Text with EEA relevance)
- F9 Substituted by Commission Delegated Regulation (EU) 2020/1737 of 14 July 2020 amending Regulation (EC) No 273/2004 of the European Parliament and of the Council and Council Regulation (EC) No 111/2005 as regards the inclusion of certain drug precursors in the list of scheduled substances (Text with EEA relevance)
- F10 Substituted by Commission Delegated Regulation (EU) 2020/1737 of 14 July 2020 amending Regulation (EC) No 273/2004 of the European Parliament and of the Council and Council Regulation (EC) No 111/2005 as regards the inclusion of certain drug precursors in the list of scheduled substances (Text with EEA relevance)
- F11 Substituted by Commission Delegated Regulation (EU) 2020/1737 of 14 July 2020 amending Regulation (EC) No 273/2004 of the European Parliament and of the Council and Council Regulation (EC) No 111/2005 as regards the inclusion of certain drug precursors in the list of scheduled substances (Text with EEA relevance)

# [F1CATEGORY 2

#### **SUBCATEGORY 2A**

Substance	CN designation (if different)	CN code <sup>0</sup>	CAS No <sup>0</sup>
Acetic anhydride		2915 24 00	108-24-7

#### **SUBCATEGORY 2A**

The salts of the substances listed in this category, whenever the existence of such salts is possible.

## **SUBCATEGORY 2B**

Substance	CN designation (if different)	CN code <sup>a</sup>	CAS No b
Phenylacetic acid		2916 34 00	103-82-2
Anthranilic acid		[F12ex 2922 43 00]	118-92-3
Piperidine		2933 32 00	110-89-4
Potassium permanganate		2841 61 00	7722-64-7

The salts of the substances listed in this category, whenever the existence of such salts is possible.

- **a** OJ L 290, 28.10.2002, p. 1.
- The CAS No is the 'chemical abstracts service registry number', which is a unique numeric identifier specific to each substance and its structure. The CAS No is specific to each isomer and to each salt of each isomer. It must be understood that the CAS Nos for the salts of the substances listed above will be different to those given.

#### **Textual Amendments**

F12 Substituted by Commission Delegated Regulation (EU) 2020/1737 of 14 July 2020 amending Regulation (EC) No 273/2004 of the European Parliament and of the Council and Council Regulation (EC) No 111/2005 as regards the inclusion of certain drug precursors in the list of scheduled substances (Text with EEA relevance)

## **CATEGORY 3**

Substance	CN designation(if different)	CN code <sup>a</sup>	CAS Nob
Hydrochloric acid	Hydrogen chloride	2806 10 00	7647-01-0
Sulphuric acid		[F132807 00 00]	7664-93-9
Toluene		2902 30 00	108-88-3
Ethyl ether	Diethyl ether	2909 11 00	60-29-7
Acetone		2914 11 00	67-64-1
Methylethylketone	Butanone	2914 12 00	78-93-3

The salts of the substances listed in this category, whenever the existence of such salts is possible and not being the salts of hydrochloric acid and sulphuric acid.

- **a** OJ L 290, 28.10.2002, p. 1.
- b The CAS No is the 'chemical abstracts service registry number', which is a unique numeric identifier specific to each substance and its structure. The CAS No is specific to each isomer and to each salt of each isomer. It must be understood that the CAS Nos for the salts of the substances listed above will be different to those given.

Document Generated: 2024-01-13

Changes to legislation: There are outstanding changes not yet made to Regulation (EC) No 273/2004 of the European Parliament and of the Council. Any changes that have already been made to the legislation appear in the content and are referenced with annotations. (See end of Document for details) View outstanding changes

#### **Textual Amendments**

F13 Substituted by Commission Delegated Regulation (EU) 2020/1737 of 14 July 2020 amending Regulation (EC) No 273/2004 of the European Parliament and of the Council and Council Regulation (EC) No 111/2005 as regards the inclusion of certain drug precursors in the list of scheduled substances (Text with EEA relevance)

# ANNEX II

Substance	Threshold
Acetic anhydride	1001
Potassium permanganate	100 kg
Anthranilic acid and its salts	1 kg
Phenylacetic acid and its salts	1 kg
Piperidine and its salts	0,5 kg

# ANNEX III

1. Model declaration relating to individual transactions (category 1 or 2)

Document Generated: 2024-01-13

Changes to legislation: There are outstanding changes not yet made to Regulation (EC) No 273/2004 of the European Parliament and of the Council. Any changes that have already been made to the legislation appear in the content and are referenced with annotations. (See end of Document for details) View outstanding changes

CUSTOMER DECLARATION OF SPECIFIC USE(S) OF THE SCHEDULED CATEGORY 1 OR 2 SUBSTANCE (individual transactions)			
I/We,			
Name:			
Address:			
Reference number of ▶ Licence/registration:			
issued on			
(name and address of the datherny)			
and without time limit/valid until			
have ordered from			
Name:			
Address:			
the following substance			
Description:			
Combined nomenclature (CN) code:			
The substance will be used solely for			
I/We hereby certify that the substance referred to above will not be re-sold or otherwise supplied to any other customer unless the latter furnishes a declaration of use in accordance with this model or, for category 2 substances, a declaration relating to multiple transactions.			
Signature Name:			
(in block capitals)			
Position: Date:			

2. Model declaration relating to multiple transactions (category 2)

Document Generated: 2024-01-13

Changes to legislation: There are outstanding changes not yet made to Regulation (EC) No 273/2004 of the European Parliament and of the Council. Any changes that have already been made to the legislation appear in the content and are referenced with annotations. (See end of Document for details) View outstanding changes

CUSTOMER DECLARATION OF SPECIFIC USE(S) OF THE SCHEDULED CATEGORY 2 SUBSTANCE (multiple transactions)	
I/We,	
Name:	
Address:	
Registration reference number:	
issued on by	
(name and address of t	he authority)
and without time limit/valid until	
intend to order from	
Name:	
Address:	
the following substance	
Description:	
Combined nomenclature (CN) code:	
The substance will be used solely for	
and represents a quantity that is normally considered sufficient for	
I/We hereby certify that the substance referred to above will not be re-sold or supplied to any other customer unlessubmits a similar declaration of use or a declaration relating to individual transactions.	s the latter
Signature: Name: (in bl	ock capitals)
Position: Date:	. ,
Toditon.	

#### **Changes to legislation:**

There are outstanding changes not yet made to Regulation (EC) No 273/2004 of the European Parliament and of the Council. Any changes that have already been made to the legislation appear in the content and are referenced with annotations.

View outstanding changes

#### Changes and effects yet to be applied to:

- Annex 1 Table addition by EUR 2020/1737 Regulation (This amendment by the EU not applied to legislation.gov.uk because it is brought into force after IP completion day.)
- Annex 2 Table addition by EUR 2020/1737 Regulation (This amendment by the EU not applied to legislation.gov.uk because it is brought into force after IP completion day.)
- Art. 1 words substituted by S.I. 2019/742 reg. 13(2)
- Art. 3(2) words omitted by S.I. 2019/742 reg. 13(4)(a)
- Art. 3(6) words omitted by S.I. 2019/742 reg. 13(4)(b)
- Art. 3(7) omitted by S.I. 2019/742 reg. 13(4)(c)
- Art. 3(8) words substituted by S.I. 2019/742 reg. 13(4)(d)(i)
- Art. 4(1) words substituted by S.I. 2019/742 reg. 13(5)(a)
- Art. 4(3) words substituted by S.I. 2019/742 reg. 13(5)(b)
- Art. 4(4) substituted by S.I. 2019/742 reg. 13(5)(c)
- Art. 5(7) substituted by S.I. 2019/742 reg. 13(6)
- Art. 7 words substituted by S.I. 2019/742 reg. 13(7)
- Art. 8(3) substituted by S.I. 2019/742 reg. 13(8)
- Art. 9(1) words substituted by S.I. 2019/742 reg. 13(9)
- Art. 10 omitted by S.I. 2019/742 reg. 13(10)
- Art. 11 omitted by S.I. 2019/742 reg. 13(10)
- Art. 12 omitted by S.I. 2019/742 reg. 13(10)
- Art. 13 substituted by S.I. 2019/742 reg. 13(11)
- Art. 13a omitted by S.I. 2019/742 reg. 13(12)
- Art. 13b(1) omitted by S.I. 2019/742 reg. 13(13)(a)
- Art. 13b(2) words substituted by S.I. 2019/742 reg. 13(13)(b)
- Art. 13b(3)(4) omitted by S.I. 2019/742 reg. 13(13)(c)
- Art. 14 omitted by S.I. 2019/742 reg. 13(14)
- Art. 14a omitted by S.I. 2019/742 reg. 13(14)
- Art. 15 words substituted by S.I. 2019/742 reg. 13(15)
- Art. 15a substituted by S.I. 2019/742 reg. 13(16)
- Art. 16 omitted by S.I. 2019/742 reg. 13(17)

# Changes and effects yet to be applied to the whole legislation item and associated provisions

- Signature words omitted by S.I. 2019/742 reg. 13(18)
- Art. 2(a) words substituted by S.I. 2019/742 reg. 13(3)(a)
- Art. 2(c) words substituted by S.I. 2019/742 reg. 13(3)(b)
- Art. 3(8)(c) omitted by S.I. 2019/742 reg. 13(4)(d)(ii)